Evidence map›Paper›PMID 42426343›Full record

ArticleJournal of thrombosis and thrombolysis2026

Antiplatelet effects of oral anticoagulants in patients with atrial fibrillation: ex-vivo studies.

Giulia Renda, Valentina Bucciarelli, Giulia Barbieri, Paola Lanuti, Martina Berteotti, Gelsomina Malatesta, Francesca Cesari, Betti Giusti, Anna Maria Gori, Rossella Marcucci and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of thrombosis and thrombolysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Giulia RendaDepartment of Neuroscience, Imaging and Clinical Sciences and Center for Advanced Studies and Technology, G. d'Annunzio University Chieti-Pescara, Chieti, Italy.
Valentina BucciarelliCardiovascular Sciences Department, Azienda Ospedaliero-Universitaria delle Marche, Ancona, Italy.
Giulia BarbieriDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Paola LanutiDepartment of Medicine and Aging Sciences and Center for Advanced Studies and Technology, G. d'Annunzio University Chieti-Pescara, Chieti, Italy.
Martina BerteottiDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Gelsomina MalatestaCardiology Unit, National Institute of Health and Science on Aging (INRCA), Ancona, Italy.
Francesca CesariDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Betti GiustiDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Anna Maria GoriDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Rossella MarcucciDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Raffaele De CaterinaChair of Cardiology, University of Pisa, Pisa, Italy. raffaele.decaterina@unipi.it.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The impact of direct oral anticoagulants (DOACs) on platelet function is still unclear. We conducted an observational study aimed at assessing the effect of DOACs on platelet function in patients with atrial fibrillation (AF) treated with the direct thrombin inhibitor dabigatran (n = 22) and the Factor Xa (FXa) inhibitors rivaroxaban (n = 20), apixaban (n = 22) and edoxaban (n = 12), compared with patients treated with the vitamin K antagonist warfarin (n = 26) and with untreated patients without AF as controls (n = 23). We evaluated thrombin generation by calibrated automated thrombogram (CAT); light transmittance platelet aggregation (LTA) induced by adenosine diphosphate (ADP), thrombin, thrombin receptor-activating peptide (TRAP) and tissue factor (TF); serum thromboxane (TX) generation; the expressions of protease-activated receptor (PAR)-1 and P-selectin on the platelet surface. Thrombin generation was reduced in patients treated with FXa inhibitors as well as in patients treated with warfarin compared to controls. Patients treated with rivaroxaban and apixaban showed significantly reduced LTA compared to controls with all used agonists; while patients treated with dabigatran and edoxaban showed reduced thrombin- and TF-induced aggregation, respectively. TXB

Indexed as

Antiplatelet effectsDirect oral anticoagulantsDOACsOral anticoagulantsPlatelets

Identifiers

PMID42426343

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.